Abbott Laboratories ABT is slated to report its second-quarter 2024 results on Jul 18, before the opening bell. The company posted adjusted earnings per share (EPS) of 98 cents in the last quarter, which topped the Zacks Consensus Estimate by 2.08%. In the trailing four quarters, its earnings exceeded the Zacks Consensus Estimate on all four occasions, the average beat being 2.39%. Q2 Estimates The Zacks Consensus Estimate for ABT’s second-quarter 2024 revenues is pegged at $10.35 billion. This suggests a 3.8% rise from the year-ago reported figure. The Zacks Consensus Estimate for its second-quarter 2024 EPS of $1.10 indicates a 1.9% improvement from the 2023 comparable figure. Estimate Revision Trend Ahead of Earnings Estimates for Abbott’s Q2 earnings remained unchanged at $1.10 per share in the past 60 days. Let's briefly look at how things have progressed for the MedTech major leading up to this announcement. Factors at Play Established Pharmaceuticals (EPD) Abbott’s EPD business consistently benefits from offering a broad portfolio of products that are designed to meet the local needs of fast-growing emerging markets. In the second quarter of 2024, the division is likely to have held its impressive streak of strong performance across several regions and therapeutic areas, including respiratory, women's health and central nervous system/pain management. Similar to the past quarters, the performance may have boosted Abbott’s overall profitability and led to solid margin expansion. In addition, the company is likely to have advanced with its plan to introduce biosimilars in key emerging markets. These breakthrough treatment options focused on oncology, women's health and respiratory diseases enhance its existing branded generic medicines portfolio. The Zacks Consensus Estimate for the segment’s revenues shows a year-over-year increase of 1.3% in the second quarter of 2024. Diagnostics The Diagnostics arm is expected to have been driven by the widespread adoption of its top-tier systems and high testing demand across a variety of settings, including hospitals, laboratories, physician offices, retail pharmacies and blood screening facilities. In the core lab business, the continued rollout of Abbott's Alinity testing platform and increased routine diagnostic testing are likely to have boosted the revenues in the to-be-reported quarter. Furthermore, the new FDA-approved i-STAT TBI Plasma test may have favorably impacted the Point of Care diagnostics sales. Meanwhile, the demand for COVID-19 testing nosedived over the past several quarters and marred the segment’s growth. We expect to see another quarter of year-over-year decline in Diagnostics revenue this time. However, the magnitude of this decline may have reduced because, during the second quarter of 2023, Diagnostic revenues were already soft and on a downward trend (in May 2023, WHO declared an end to COVID-19 as a public health emergency). Going by the Zacks Consensus Estimate, Diagnostics revenues are likely to have decreased 4.4% year over year in the second quarter of 2024. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise Abbott Laboratories price-eps-surprise | Abbott Laboratories Quote Medical Devices The segment has been a standout performer for the company, steadily growing over the last several quarters and making a notable impact on the margin performance. In the second quarter of 2024, the business’ sales are likely to have been led by the diabetes care division. This is expected to have been driven by the Freestyle Libre sensing technology, which alone surged 23% in the first quarter. We assume Abbott to have capitalized on Libre’s substantial growth opportunities to maintain its strong sales momentum. In addition, the new Lingo and Libre Rio over-the-counter CGM systems, both of which were FDA-cleared in early June, are also expected to have positively boosted the company’s second-quarter revenues. Turning to Abbott’s Cardiovascular business, the electrophysiology portfolio is likely to have delivered robust performance across the key regions and product categories, particularly in the ablation catheters and cardiac mapping areas. In April, the company secured the FDA’s approval for the first-of-its-kind innovation for people with chronic limb-threatening ischemia below the knee. Within Structural Heart, we expect the company to report robust performance in the high-growth areas, including TAVR, mitral and tricuspid repair, while newer products such as Navitor, Amulet, and TriClip, along with the prime MitraClip, are likely to have registered strong sales as well. Within the Rhythm Management arm, Abbott’s new leadless pacemaker, AVEIR, is making strides in dual chamber pacing, following its rapid success in the single chamber pacing segment. Furthermore, the growth in the Neuromodulation division may have been led by the sales of Eterna, a rechargeable neurostimulation device for pain management. All these developments are anticipated to have greatly boosted Abbott’s top line in the quarter under review. According to the Zacks Consensus Estimate, the Medical device segment’s revenues are expected to improve 9.1% year over year in the second quarter. Nutrition In this division, sales of pediatric nutritionals are likely to have been robust as Abbott continues to capture market share in the infant formula business. We also anticipate solid growth across the international portfolio of infant formula, toddler, and adult nutrition brands in the second quarter of 2024. Furthermore, Abbott’s new nutrition shake Protality may have positively impacted the Nutrition revenues. The product was launched earlier this year and features a formulation similar to the company’s popular Ensure Max Protein drink. The leading Ensure family of products is also likely to have significantly favored the top-line growth in the quarter under review. The Zacks Consensus Estimate indicates a 3.5% improvement in the segment’s revenues in the second quarter compared to the same period in 2023. What Our Model Suggests Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates. However, that is not the case here, as you can see below: Earnings ESP: Abbott has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #3. Stocks Worth a Look Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time: Hims & Hers Health HIMS has an Earnings ESP of +19.28% and a Zacks Rank #1. The company is expected to release second-quarter 2024 results on Aug 5. You can see the complete list of today’s Zacks #1 Rank stocks here. HIMS’ earnings surpassed estimates in three of the trailing four quarters and missed the same once, with the average surprise being 79.17%. The Zacks Consensus Estimate for the company’s second-quarter EPS is expected to surge 266.7% from the year-ago quarter figure. HCA Healthcare HCA has an Earnings ESP of +7.10% and a Zacks Rank #2. The company is slated to release second-quarter 2024 results on Jul 23. HCA’s earnings surpassed estimates in three of the trailing four quarters, with the average surprise being 5.64%. The Zacks Consensus Estimate for HCA Healthcare’s second-quarter EPS is expected to surge 15.9% from the year-ago quarter figure. Enovis ENOV has an Earnings ESP of +3.70% and a Zacks Rank #2. The company is likely to release second-quarter 2024 results on Aug 1. The company’s earnings surpassed estimates in all the trailing four quarters, with the average surprise being 6.18%. The Zacks Consensus Estimate for ENOV’s 2024 second-quarter EPS is expected to improve 24.1% from the year-ago reported figure. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT):Free Stock Analysis Report HCA Healthcare, Inc. (HCA):Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS):Free Stock Analysis Report Enovis Corporation (ENOV):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Here's How Abbott (ABT) is Placed Ahead of Q2 Earnings Release
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...